Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)
Coronary Atherosclerosis
About this trial
This is an interventional treatment trial for Coronary Atherosclerosis focused on measuring Olmesartan medoxomil, Epicardial adipose tissue, Multidetector Computed Tomography
Eligibility Criteria
Inclusion Criteria:
- coronary artery stenosis between 30% and 70% determined by CCTA in essential hypertension patients
- resting diastolic blood pressure (DBP) between 90 and 110 mmHg
- type A and B for coronary artery vascular lesions
Exclusion Criteria:
- secondary hypertension
- coronary artery stenosis less than 30% or greater than 70% determined by CCTA
- contraindications to treatment with olmesartan medoxomil (allergy, glaucoma, digestive ulcer, is currently taking phosphodiesterase-5 inhibitor)
- resting systolic blood pressure (SBP) > 200 mmHg or resting diastolic blood pressure (DBP) > 110 mmHg
- Severe calcification, distortion or type C for coronary artery vascular lesions
- pregnancy
- unwillingness or inability to provide informed consent
Sites / Locations
- Chinese PLA General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Olmesartan medoxomil
Antihypertensive medication
Drug: Olmesartan medoxomil tablets(Daiichi Sankyo Inc, Japan). The initial dose is 20mg once daily. If blood pressure requiring further reduction after two weeks, olmesartan medoxomil may be increased to 40mg once daily.
Drug:Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except angiotensin-Converting Enzyme Inhibitors inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs). The drug dose must be individualized.